SCHEDULE: Bank of America Discloses Minor Stake in Aptevo Therapeutics

Bank of America Corp /DE/ has filed an amended Schedule 13G, reporting beneficial ownership of 86 shares, representing 0.0% of Aptevo Therapeutics Inc.'s common stock.

Summary

• Bank of America Corp /DE/ filed an Amendment No. 1 to Schedule 13G regarding Aptevo Therapeutics Inc. common stock.
• The filing reports beneficial ownership of 86 shares of Aptevo Therapeutics Inc. common stock.
• This ownership represents 0.0% of the class of securities.
• The percentage calculation is based on 3,287,918 outstanding shares, as referenced in Aptevo Therapeutics Inc.'s Form 10-Q filed on August 11, 2025.
• Bank of America Corp /DE/ holds shared voting power and shared dispositive power over all 86 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard regulatory disclosure of a negligible ownership stake by a financial institution, carrying no significant positive or negative implications for the issuer.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Aptevo Therapeutics Inc.'s future outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine regulatory disclosure by a financial institution regarding a negligible ownership stake in a publicly traded company. It does not provide specific insights into broader industry trends for Aptevo Therapeutics Inc. or the biotechnology sector, nor does it reflect competitive positioning.

Stakeholder Impact

• The reported 0.0% beneficial ownership by Bank of America Corp /DE/ is negligible and is expected to have no material impact on shareholders, employees, customers, suppliers, or creditors of Aptevo Therapeutics Inc.

Key Dates

Keywords

Aptevo Therapeutics, Bank of America, Schedule 13G, Common Stock, Beneficial Ownership, SEC Filing, Institutional Ownership, 03835L504